Skip to content

Minoxidil 2% for Eyebrow Enhancement

Efficacy and Tolerability of Minoxidil 2% for Eyebrow Enhancement : A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01672307
Enrollment
40
Registered
2012-08-24
Start date
2012-09-30
Completion date
2013-03-31
Last updated
2013-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotrichosis of Eyebrows, Thinning Eyebrows

Keywords

hypotrichosis of eyebrows, thinning eyebrows, minoxidil, placebo, randomized

Brief summary

The purpose of the study is to compare minoxidil 2% versus placebo in enhancement of eyebrows.

Interventions

DRUGMinoxidil lotion 2%

Minoxidil lotion 2% is applied twice daily to one eyebrow.

DRUGPlacebo

Placebo is applied twice daily to the other eyebrow.

Sponsors

Mae Fah Luang University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* male or female aged 18-40 years * hypotrichosis of eyebrows * healthy * informed consent obtained

Exclusion criteria

* no underlying diseases * no alopecia areata or trichotillomania * no thyroid diseases * no pregnancy or breast feeding * no previous eyebrow tattoo, trauma or accident. * no history of eyebrow or hair medications in 6 months * no history of minoxidil or its ingredient allergy * no history of eyebrow surgery.

Design outcomes

Primary

MeasureTime frame
The change of global photographic assessment after 16 weeks from baselinebaseline and 16 weeks

Secondary

MeasureTime frame
The change of hair diameter after 16 weeks from baselinebaseline and 16 weeks

Other

MeasureTime frame
The change in number of hairs after 16 weeks from baselinebaseline and 16 weeks
Number of participants with adverse events. Adverse events include any skin rashes or symptoms.16 weeks
Patient satisfaction by self-assessment questionnaires16 weeks

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026